Amylyx Pharmaceuticals, Inc.
Support and Resistance Levels
Past performance
News About AMLX
All events for AMLX
All deals for AMLX
Financial Ratios
Financial Statements
AMLX vs Sector & Peers
About Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts. Website amylyx.com
Headquarters Cambridge, MA, US